REG - Shield Therapeutics - Block listing Interim Return

Shield TherapeuticsAnnouncement

03/10/2023 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20231003:nRSC4420Oa&default-theme=true

RNS Number : 4420O  Shield Therapeutics PLC  03 October 2023

 

Shield Therapeutics plc

("Shield" or the "Company" or the "Group")

 

Block Listing 6 Monthly Return

 

  Name of applicant:                                                               SHIELD THERAPEUTICS PLC

 Name of scheme:                                                                   Shield Therapeutics Retention Share Plan
 Period of return:                        From:                                    31 March 2023   To:             30 September 2023
 Balance of unallotted securities under scheme(s) from previous return:            39,794
 Plus:  The amount by which the block scheme(s) has been increased since the       NIL
 date of the last return (if any increase has been applied for):
 Less:  Number of securities issued/allotted under scheme(s) during period         NIL
 (see LR3.5.7G):
 Equals:  Balance under scheme(s) not yet issued/allotted at end of period:        39,794

 

 Name of applicant:                                                                SHIELD THERAPEUTICS PLC

 Name of scheme:                                                                   Shield Therapeutics plc 2016 Company Share Option Plan
 Period of return:                        From:                                    31 March 2023        To:                  30 September 2023
 Balance of unallotted securities under scheme(s) from previous return:            341,020
 Plus:  The amount by which the block scheme(s) has been increased since the       NIL
 date of the last return (if any increase has been applied for):
 Less:  Number of securities issued/allotted under scheme(s) during period         NIL
 (see LR3.5.7G):
 Equals:  Balance under scheme(s) not yet issued/allotted at end of period:        341,020

 

 

  Name of applicant:                                                               SHIELD THERAPEUTICS PLC

 Name of scheme:                                                                   The Shield Therapeutics plc 2016 Long Term Incentive Plan
 Period of return:                        From:                                    31 March 2023         To:                   30 September 2023
 Balance of unallotted securities under scheme(s) from previous return:            24,273
 Plus:  The amount by which the block scheme(s) has been increased since the       NIL
 date of the last return (if any increase has been applied for):
 Less:  Number of securities issued/allotted under scheme(s) during period         NIL
 (see LR3.5.7G):
 Equals:  Balance under scheme(s) not yet issued/allotted at end of period:        24,273

 

 

 

 

 

 Name of applicant:                                                                SHIELD THERAPEUTICS PLC
 Name of scheme:                                                                   Shield Therapeutics Retention and Performance Share Plan
 Period of return:                        From:                                    31 March 2023        To:                  30 September 2023
 Balance of unallotted securities under scheme(s) from previous return:            2,870,838
 Plus:  The amount by which the block scheme(s) has been increased since the       NIL
 date of the last return (if any increase has been applied for):
 Less:  Number of securities issued/allotted under scheme(s) during period         NIL
 (see LR3.5.7G):
 Equals:  Balance under scheme(s) not yet issued/allotted at end of period:        2,870,838

 

 Name of contact:              Lucy Huntington-Bailey
 Telephone number of contact:  +44 (0) 191 511 8500

 

For further information please contact:

 

 Shield Therapeutics plc                                                                        www.shieldtherapeutics.com (http://www.shieldtherapeutics.com/)
 Greg Madison, CEO                                                                              +44 (0) 191 511 8500
 Hans-Peter Rudolf, CFO

 Nominated Adviser and Joint Broker
 Peel Hunt LLP
 James Steel/Patrick Birkholm                                                                   +44 (0)20 7418 8900

 Joint Broker

 Cavendish Capital Markets Ltd

 Geoff Nash/ George Dollemore/Nigel Birks/Harriet                                               +44 (0)20 7220 0500
 Ward

 Financial PR & IR Advisor
 Walbrook PR
 Lianne Applegarth/Alice Woodings                                                               +44 (0)20 7933 8780 or shield@walbrookpr.com (mailto:shield@walbrookpr.com)

 Investor Contact (US Advisor)

 LifeSci Advisors, LLC

 John Mullaly                                                                                   +1 617 429 3548 or jmullaly@lifesciadvisors.com

 

About Accrufer®/Feraccru®

Accrufer®/Feraccru® (ferric maltol) is a novel, stable, non-salt based oral
therapy for adults with iron deficiency, with or without anemia.
Accrufer®/Feraccru® has a novel mechanism of action compared to other oral
iron therapies and has been shown to be an efficacious and well-tolerated
therapy in a range of clinical trials. More information about
Accrufer®/Feraccru®, including the product label, can be found at:
www.accrufer.com (http://www.accrufer.com) and www.feraccru.com
(http://www.feraccru.com)

 

About Shield Therapeutics plc

Shield is a commercial stage specialty pharmaceutical company with a focus on
addressing iron deficiency with its lead product Accrufer®/Feraccru® (ferric
maltol). The Group has launched Accrufer® in the US and Feraccru® is
commercialized in the UK and European Union by Norgine B.V., who also have the
marketing rights in Australia and New Zealand. Shield also has an exclusive
license agreement with Beijing Aosaikang Pharmaceutical Co., Ltd., for the
development and commercialization of Accrufer® / Feraccru® in China, Hong
Kong, Macau and Taiwan, with Korea Pharma Co., Ltd. in the Republic of Korea,
and with KYE Pharmaceuticals Inc. in Canada.

Accrufer®/Feraccru® has patent coverage until the mid-2030s

Accrufer®/Feraccru® are registered trademarks of the Shield Group

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  BLRDZMGGNZNGFZM